Geography axis: coverage anchored in the United States. Pair with exactly one subject category (Pharma, Policy & Markets, Digital Health, Medical Devices or a Therapy Area). Company, regulator and payer go in tags.
Geography axis: coverage anchored in the United States. Pair with exactly one subject category (Pharma, Policy & Markets, Digital Health, Medical Devices or a Therapy Area). Company, regulator and payer go in tags.
A CVS Health white paper using Aetna claims data finds GLP-1s offset their full cost to plan sponsors only at $350 per month — well below current employer prices of …
Measles infections in the United States and Mexico have already exceeded all of 2025, with Pennsylvania recording five deaths and more than 1,000 infections as vaccine exemptions reach an all-time …
A matched cohort of 52,330 women aged 45 to 59 found no excess risk of heart attack, stroke, blood clots, or death over 12 years — with no meaningful difference …
The US Department of Labor finalized a rule on October 29, 2026 requiring pharmacy benefit managers to disclose rebates, spread compensation and other payments to large self-insured employer plans. It …
Phase III DeLLphi-305 data show tarlatamab plus durvalumab extended median overall survival to 21.1 months versus 12.7 months with durvalumab alone in extensive-stage small cell lung cancer maintenance.
CMS has finalized GLOBE, a mandatory most-favored-nation rebate model for high-spend Medicare Part B drugs starting January 1, 2027. It is far narrower than proposed, faces a PhRMA lawsuit, and …
Johnson & Johnson’s oral RIPTAC molecule JNJ-6143 cut prostate-specific antigen (PSA) levels by at least half in 77% of evaluable patients at 50 mg in phase 1 data presented at …
Belgium’s deputy prime minister has called on the EU to deploy its Anti-Coercion Instrument against Washington’s most-favored-nation drug pricing policy, as eight member states weigh a joint pharmaceutical task force.
Phase 3 data for Merck & Co. and Moderna’s personalized mRNA cancer vaccine intismeran autogene were presented at ESMO’s Presidential Symposium in Madrid, days after a pre-conference data leak.
On October 14, 2026, the FDA announced the Rare Disease Framework Initiative to develop a fit-for-purpose framework for rare disease drug development, led by its Rare Disease Innovation Hub, with …
You must be logged in to post a comment.